lead AcTafactors
targeted TNFs
targeted cell membrane lead
systemic toxicity
systemic use
systemic toxicities
biological activity
superior therapeutic indexes Tumor Necrosis Factor
relevant murine tumor models
engineered immuno-cytokines
non-targeted cells
novel class of cell
lead optimization program
pre-clinical proof
extraordinary antitumor activity
clinical development
cell- specific targeting domain
cancer treatment
concept study
single-chain TNFs
ERC Advanced Grant project
effective AcTafactor anti-cancer therapy
potential market approval
avidity effects
hypotension
vasculature
context
multiple organ failure
leukopenia
neo
homotrimeric pro-inflammatory cytokine
mutations
ability
recovery
resulting molecules
affinity
properties
step
receptor
shock